Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: Correlation with DNA topoisomerase II-alpha and p53 expression

Human Pathology

Volumn 30, Issue 4, 1999, Pages 384-391

  Monnin, Kimberly A ^b   Bronstein, Igor B ^b   Gaffney, David K ^b   Holden, Joseph A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Camptothecin; DNA topoisomerase I; DNA topoisomerase II alpha; P53; Transitional cell carcinoma

Indexed keywords

DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN P53;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; ENZYME ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

EID: 0032893502     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0046-8177(99)90112-0     Document Type: Article

References (43)

1. Pommier Y: Eukaryotic DNA topoisomerase I: Genome gate keeper and its intruders, camptothecins. Semin Oncol 23:3-10, 1996 (suppl 3)
2. Potmesil M: Camptothecins: From bench research to hospital wards. Cancer Res 54:1431-1439, 1994
3. Holden JA: Human deoxyribonucleic acid topoisomerases: Molecular targets of anticancer drugs. Ann Clin Lab Sci 27:402-412, 1997
4. Gilmour DS, Pflugfelder G, Wang JC, et al: Topoisomerase I interacts with transcribed regions in drosophila cells. Cell 44:401-407, 1986
5. Stewart AF, Schutz G: Camptothecin-induced in vivo topoisomerase I cleavages in the transcriptionally active tyrosine aminotransferase gene. Cell 50:1109-1117, 1987
6. Stewart L, Redinbo MR, Qiu X, et al: A model for the mechanism of human topoisomerase I. Science 279:1534-1542, 1998
7. Nitiss JL, Wang JC: Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharm 50:1095-1102, 1996
8. Hsiang Y, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49:5077-5082, 1989
9. Ryan AJ, Squires S, Strutt HL, et al: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucl Acid Res 19:3295-3300, 1991
10. Gerrits CJH, de Jonge MJA, SchellensJHM, et al: Topoisomerase inhibitors: The relevance of prolonged exposure for present clinical development. BrJ Cancer 76:952-962, 1997
11. Siu LL, Oza AM, Eisenhauer EA, et al: Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks. J Clin Oncol 16:1122-1130, 1998
12. Hsaing Y, Hertzberg R, Hecht S, et al: Camptothecin induces protein-linked DNA breaks vis mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878, 1985
13. Bjornsti MA, Benedetti P, Viglianti GA, et al: Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: Restoration of sensitivity of the cells to the antitumor drug camptothecin. Cancer Res 49:6318-6323, 1989
14. Giovanella BC, StehlinJS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
15. Giovanella BC, Hinz HR, Kozielski AJ, et al: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res 51:3052-3055, 1991
16. Ardizsoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer. J Clin Oncol 15:2090-2096, 1997
17. Saylors R, Stewart CF, Zamboni WC, et al: Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors. J Clin Oncol 16:945-952, 1998
18. Creemers GJ, Bolis G, Scarfone G, et al: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer. J Clin Oncol 14:3056-3061, 1996
19. Kraut EH, Crowley JJ, Wade JL, et al: Evaluation of topotecan in resistant and relapsing multiple myeloma. J Clin Oncol 16:589-592, 1998
20. Pitot HC, Wender DB, O'Connell MJ, et al: Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 15:2910-2919, 1997
21. Ohno R, Okada K, Masaoka T, et al: An early phase II study of CPT-11: A new derivative of camptothecin for the treatment of leukemia and lymphoma. J Clin Oncol 8:1907-1912, 1990
22. Tolcher AW, O'Shaughnessy JA, Weiss RB, et al: A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Can Res 3:755-760, 1997
23. Madden KR, Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: Hypersensitivity of clonal isolates to camptothecin. Cancer Res 52:525-532, 1992
24. Holden JA, Rahn MP, Jolies CJ, et al: Immunohistochemical detection of DNA topoisomerase I in formalin-fixed, paraffin wax embedded normal tissues and in ovarian carcinomas. J Clin Pathol Mol Pathol 50:247-253, 1997
25. Caserini C, Pratesi G, Tortoreto M, et al: Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors. Clin Cancer Res 3:955-961, 1997
26. Whitacre CM, Berger NA: Factors affecting topotecaninduced programmed cell death: Adhesion protects cells from apoptosis and impairs cleavage of poly (ADP-ribose) polymerase. Cancer Res 57:2157-2163, 1997
27. Lynch BJ, Guinee DG, Holden JA: Human DNA topoisomerase II-alpha: A new marker of cell proliferation in invasive breast cancer. HUM PATHOL 28:1180-1188, 1997
28. Lowe SW, Ruley HE, Jacks T, et al: p53-Dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 74:957-967, 1993
29. Ash JE: Epithelial tumors of the bladder. J Urol 44:135-145, 1940
30. Bronstein IB, Vorobyev S, Timofeev A, et al: Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies. Oncol Res 8:17-25, 1996
31. Holden JA, Perkins SL, Snow GW, et al: Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas. Am J Clin Pathol 104:54-59, 1995
32. Lynch BJ, HoldenJA, Buys SS, et al: Pathobiologic characteristics of hereditary breast cancer. HUM PATHOL 29:1140-1144, 1998
33. Heck MMS, Hittelman WN, Earnshaw WC: Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A 85:1086-1090, 1988
34. Vollmer RT, Humphrey PA, Swanson PE, et al: Invasion of the bladder by transitional cell carcinoma. Cancer 82:715-723, 1998
35. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254, 1976
36. Esrig D, Elmajian D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994
37. Popov Z, Hoznek A, Colombel M, et al: The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80:1472-1481, 1997
38. Valenti M, Nieves-Neira W, Kohlhagen G, et al: Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells. Mol Pharm 52:82-87, 1997
39. McDonald AC, Brown R: Induction of p53-dependent and p53 independent cellular responses by topoisomerase I inhibitors. Br J Cancer 78:745-751, 1998
40. Rowinsky EK, Kaufman SH: Topotecan in combination chemotherapy. Semin Oncol 24:s20-s26, 1997 (suppl 20)
41. Masuda N, Fukuoka M, Kusunoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10:1225-1229, 1992
42. Kudoh S, Fujiwara Y, Takada Y, et al: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. J Clin Oncol 16:1068-1074, 1998
43. Guinee DG, Holden JA, Benfield JR, et al: Comparison of DNA topoisomerase II-alpha expression in small cell and non small cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response. Cancer 78:729-735, 1996